| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 13.8 | 14.7 |
| Gross profit | 12.0 | 12.8 |
| Profit before tax | -14.2 | -12.9 |
| Net income | -14.2 | -12.9 |
| EPS (diluted, $ a share) | $-0.52 | $-0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -5.8% |
|---|---|
| Gross margin | 86.7% |
| Operating margin | -94.3% |
10-Q filed with the SEC, NASDAQ: CVRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CVRx, Inc.: key numbers
- Share price
- $0.6130Close, Nov 16
- Market cap
- $17.5M
- Shares outstanding
- 28.49MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CVRx, Inc.
All →CVRx Financial Results
CVRx reported third quarter 2026 financial results, with total revenue of $13.8 million, a 6% decrease year-over-year. The decline was primarily attributed to lower sales force productivity and challenges with a major payer, though the company expanded its U.S. active implanting centers to 262.
“While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA. With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”
Kevin Hykes, President and Chief Executive Officer of CVRx
CVRx Executive Compensation
CVRx, Inc. appointed John Landry as Chief Financial Officer, effective October 12, 2026, succeeding Jared Oasheim. Mr. Landry's compensation package includes a $500,000 base salary, a 50% target cash incentive, and initial equity awards (75% options, 25% RSUs) representing 0.80% of total common shares outstanding.
- Counterparty
- John Landry